Radiation challenge to standard bladder cancer treatment could reduce recurrence and save bladders
NCT ID NCT07268339
Summary
This study compares two approaches for treating high-risk bladder cancer that hasn't spread into the muscle layer. The standard treatment involves surgery followed by BCG immunotherapy placed directly into the bladder, which requires maintenance treatment for up to 3 years and has supply issues. The experimental approach uses targeted radiation therapy combined with a drug that makes cancer cells more sensitive to radiation. Researchers aim to see if this radiation-based approach works better than BCG at keeping the cancer from returning or progressing, potentially helping patients avoid having their bladder removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Christie
Manchester, M20 4BX, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.